Literature DB >> 11960331

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

T L Holyoake1, X Jiang, M W Drummond, A C Eaves, C J Eaves.   

Abstract

Chronic myeloid leukemia (CML) has been studied intensively for many years; yet its treatment remains problematic and its biology remains elusive. In chronic phase, the leukemic clone appears to be maintained by a small number of BCR-ABL-positive hematopoietic stem cells that differentiate normally and amplify slowly. In contrast, as these cells enter the intermediate stages of lineage restriction, their progeny are selectively expanded and generate an enlarged pool of neoplastic progenitors. Recent analyses of purified subsets of primitive CML cells have provided a coherent explanation for this dichotomous behavior of BCR-ABL-positive stem and progenitor cells based on the discovery of an unusual autocrine IL-3/G-CSF mechanism activated in them. This only partially counteracts in vivosignals that maintain normal stem cells in a quiescent state but, when active in CML stem cells, promotes their differentiation in favor of their self-renewal. In more differentiated CML progenitors, the same mechanism has a more potent mitogenic effect which is then extinguished when the cells enter the terminal stages of differentiation. Thus, further expansion of the clone is limited until inevitably additional mutations are acquired that further distort or override the regulatory mechanisms still operative in the chronic phase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960331     DOI: 10.1038/sj.leu.2402444

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  Meeting report: Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD, May 13-16, 2007.

Authors:  Linda Wolff; Steven J Ackerman; Giuseppina Nucifora
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

2.  Some dynamic aspects of hematopoietic stem cells.

Authors:  David Dingli; Jorge M Pacheco
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

Review 3.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

4.  Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

Authors:  Xiaoyan Jiang; Donna Forrest; Franck Nicolini; Ali Turhan; Joelle Guilhot; Calvin Yip; Tessa Holyoake; Heather Jorgensen; Karen Lambie; Kyi Min Saw; Emily Pang; Ranko Vukovic; Paeta Lehn; Ashley Ringrose; Miao Yu; Ryan R Brinkman; Clay Smith; Allen Eaves; Connie Eaves
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

5.  CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Authors:  Irene Dogliotti; Carmen Fava; Anna Serra; Enrico Gottardi; Filomena Daraio; Francesca Carnuccio; Emilia Giugliano; Monica Bocchia; Giuseppe Saglio; Giovanna Rege-Cambrin
Journal:  Stem Cell Investig       Date:  2017-06-23

6.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

7.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

Review 8.  Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

Authors:  Emmanuelle Passegué; Catriona H M Jamieson; Laurie E Ailles; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

9.  Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.

Authors:  Jasmine Foo; Mark W Drummond; Bayard Clarkson; Tessa Holyoake; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-09-11       Impact factor: 4.475

10.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.